Mounjaro vs Wegovy
Tirzepatide vs Semaglutide — Complete Comparison (2026)
Mounjaro (tirzepatide) is a dual GLP-1/GIP injection branded for type 2 diabetes; Wegovy (semaglutide 2.4 mg) is a GLP-1 injection branded for obesity. Both drive major weight loss, but they differ in mechanism, indication, and ceiling. Here's the evidence-based comparison.
Mounjaro vs Wegovy: At a Glance
- ✓Dual GLP-1/GIP receptor agonist
- ✓Once-weekly subcutaneous injection
- ✓FDA-approved for type 2 diabetes
- ✓Tirzepatide twin of Zepbound (obesity brand)
- ✓SURMOUNT-1 (tirzepatide): ~20.9% weight loss at 72 wks
- ✓Eli Lilly
- ✓GLP-1 receptor agonist
- ✓Once-weekly subcutaneous injection
- ✓FDA-approved for obesity / weight management
- ✓SELECT: 20% cardiovascular risk reduction
- ✓STEP-1: 14.9% weight loss at 68 weeks
- ✓Novo Nordisk
Detailed Comparison
| Feature | Mounjaro (Tirzepatide) | Wegovy (Semaglutide) |
|---|---|---|
| Generic | Tirzepatide | Semaglutide 2.4 mgBest |
| Manufacturer | Eli Lilly | Novo Nordisk |
| Mechanism | GLP-1 + GIP dual agonist | GLP-1 agonist |
| Brand Indication | Type 2 diabetes | Obesity / weight management |
| Obesity Twin | Zepbound (same drug) | Wegovy is the obesity brand |
| Administration | Once-weekly injection | Once-weekly injection |
| Weight Loss | ~20.9% at 72 wks (tirzepatide) | 14.9% at 68 wks (STEP-1) |
| CV Outcome Data | Emerging | SELECT: 20% MACE reduction |
| Side Effects | Nausea, diarrhea, constipation | Nausea, vomiting, diarrhea |
| FDA Status | Approved (diabetes 2022) | Approved (obesity 2021) |
How to Choose
Maximum Weight Loss
Tirzepatide's dual mechanism generally produces more weight loss than semaglutide — about 20.9% vs 14.9% in their respective pivotal trials.
Cardiovascular Proof
Wegovy's SELECT trial showed a 20% reduction in major cardiovascular events in obesity without diabetes — a strong point in its favor.
Indication Fit
Mounjaro is on-label for diabetes; Wegovy for obesity. For weight loss coverage, the obesity brands (Zepbound / Wegovy) matter for insurance.
Tolerability
Both cause GI side effects during titration. Some patients tolerate one better than the other — individual response varies.
Same Routine
Both are once-weekly injections with similar titration schedules and refrigeration needs. Convenience is a wash.
Cost & Access
Both are expensive without coverage. Insurance and savings programs often decide the real-world choice. Check both.
Which Should You Choose?
For pure weight loss, the evidence leans toward tirzepatide: its dual GLP-1/GIP mechanism produced roughly 20.9% weight loss at 72 weeks, compared with semaglutide's 14.9% at 68 weeks. A head-to-head diabetes trial (SURPASS-2) also found tirzepatide superior to semaglutide for both glucose and weight.
Wegovy's edge is cardiovascular evidence: the SELECT trial showed a 20% reduction in major adverse cardiovascular events in people with obesity and existing heart disease but no diabetes — the kind of hard-outcome data that matters to many prescribers.
One practical note: if your goal is weight loss, the relevant Lilly brand is usually Zepbound (the obesity-indicated tirzepatide), not Mounjaro (the diabetes brand) — they are the same drug, but indication affects coverage. Whichever you take, track your dose, weight, and side effects in Shotlee so you can judge your real response.
Mounjaro vs Wegovy: Frequently Asked Questions
Tirzepatide (Mounjaro/Zepbound) generally produces more weight loss than semaglutide (Wegovy) — about 20.9% vs 14.9% in their pivotal trials, and tirzepatide beat semaglutide head-to-head in SURPASS-2. Wegovy's advantage is proven cardiovascular benefit.
Mounjaro is tirzepatide, a dual GLP-1/GIP agonist branded for type 2 diabetes. Wegovy is semaglutide 2.4 mg, a GLP-1 agonist branded for obesity. Both are once-weekly injections.
They are the same drug (tirzepatide). Zepbound is the obesity-indicated brand and is usually the relevant one for weight-loss coverage; Mounjaro is the diabetes brand.
Wegovy's SELECT trial demonstrated a 20% reduction in major cardiovascular events in obesity without diabetes. Tirzepatide's cardiovascular outcome data is still emerging.
Yes. Shotlee tracks any GLP-1, including tirzepatide and semaglutide — dose, weight, side effects, and labs — so you can compare your results.
Track Mounjaro or Wegovy in Shotlee
Free dose logging, weight trends, and side-effect tracking for any GLP-1.
📚References & sources
Latest on Mounjaro
Ozempic, Wegovy & Beyond: How GLP-1 Drugs Are Changing What We Eat
The rise of GLP-1 medications is profoundly altering consumer spending habits and food preferences, forcing the grocery industry to adapt. Discover the science behind these changes and how businesses are responding.
7 min read
Wegovy, Mounjaro & Your Libido: How GLP-1s Reshape Desire
GLP-1 medications have transformed weight management and diabetes care, but their effects extend beyond the scale. Many users report surprising changes to their libido and sexual function. This article delves into why these powerful drugs can either boost or dampen your sex drive, offering insights from leading medical experts.
9 min read
Ozempic & Wegovy's Shadow: The Rise of Gray Market Peptides
The surge in popularity of GLP-1 medications like Ozempic and Wegovy has inadvertently fueled a growing 'gray market' for peptides. This unregulated trade, often facilitated by cryptocurrency, presents significant risks to consumers seeking cheaper alternatives or unapproved compounds.
6 min read